Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models

In conclusion, HuVac-19 was not associated with any major systemic adverse effects in the general toxicity and safety pharmacology evaluation, demonstrating that HuVac-19 is a vaccine candidate with sufficient capacity to be used in human clinical trials.PMID:37491472 | DOI:10.1007/s00204-023-03549-6

Source: Archives of Toxicology - July 25, 2023 Category: Toxicology Authors: Sang-Jin Park Min Seong Jang Kwang-Hyun Lim Joung-Wook Seo Wan-Jung Im Kang-Hyun Han Seong-Eun Kim Eunhee Jang Danbi Park Yong-Bum Kim Source Type: research